Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05735249 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
A Phase 1 study, sponsored by Arisan Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT05735249: Completed Phase 1 study, sponsored by Arisan Therapeutics.
NCT05735249 is a Phase 1 study that has completed, run by Arisan Therapeutics. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05735249, a Phase 1 study, has completed, sponsored by Arisan Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need. ARN-75039-101 study was a randomized, double-blind, placebo-controlled study that assessed the safety, tolerability, and PK of escalating single and multiple doses of ARN 75039 when administered by the oral route in healthy adult subjects in six single ascending dose (SAD - Part 1) cohorts and five multiple ascending dose (MAD - Part 2) cohorts.
Interventions
- DRUG Placebo
- DRUG ARN-75039 oral capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-01-23 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05735249
The ClinicalTrials.gov registry entry for NCT05735249 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). The listed sponsor is Arisan Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05735249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05735249 about?
NCT05735249 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects". ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need. ARN-75039-101 study was a randomized, double-blind, placebo-controlled study that assessed ...
What is the current status of trial NCT05735249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2023-01-23. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT05735249?
The interventions under investigation include: Placebo (DRUG), ARN-75039 oral capsules (DRUG).
Who is sponsoring clinical trial NCT05735249?
This trial is sponsored by Arisan Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00003211 · 94 participants · Phase 2
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
- NCT00037830 · 94 participants · Phase 2
GM1 Ganglioside Effects on Parkinson's Disease
- NCT00050947 · 94 participants · Phase 3
Pediatric Epilepsy Study
- NCT00278161 · 94 participants · Phase 2
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Similar registry start date
- NCT05684068 · started 2028-08 · NA
Dimensional Changes: Randomized Clinical Trial
- NCT07167953 · started 2028-08 · NA
The Spiral MRI Study
- NCT07215013 · started 2028-07 · NA
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
- NCT07443332 · started 2028-07 · NA
Culturally Adapted Contingency Management
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.